WuXi AppTec surpassed Lonza in H1 2026 revenue ($4.28B vs $4.17B), despite Pentagon scrutiny.
WuXi AppTec, the Chinese contract manufacturer under scrutiny from the Pentagon, isn’t slowing down. For the first time, the company appears to have generated more …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Chinese biotech firm wins initial court case against Pentagon blacklisting
WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model
Judge blocks US decision to add WuXi AppTec to Pentagon's Chinese military ties list
US judge blocks Pentagon from listing WuXi as Chinese military-linked firm
China biotech giant Wuxi AppTec sees first-half earnings surge amid US scrutiny
Breaking | US judge blocks Pentagon’s ‘Chinese military’ label for WuXi AppTec
The designation could threaten a key revenue stream for the drug contractor and complicate research, manufacturing and supply…
The Pentagon added WuXi AppTec to its Chinese military ties list, joining 188 entities. The biotech giant plans to contest the…
WuXi AppTec has lodged a claim against the Department of Defense following its addition to a list of companies associated with…
WuXi AppTec is back on the defense after being added by the Pentagon to an updated list of companies that have ties to the…
After dodging a layer of U.S. scrutiny thus far, Chinese CDMO WuXi AppTec is back in the government’s crosshairs. The company is…
WuXi AppTec seeks preliminary injunction to halt effects of its Pentagon 1260H designation, as customers wind down relationships…
